Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Initial Therapy for Mantle Cell Lymphoma with Abbreviated R-CHOP Followed By Y 90 -Ibritumomab Tiuxetan: Ten Year Follow-up of the Phase 2 ECOG-ACRIN Study E1499

Mitchell R. Smith, MD PhD, Hailun Li, PhD, Fangxin Hong, PhD, Leo I. Gordon, MD, Randy D. Gascoyne, Elisabeth Paietta, MD, Ranjana H Advani, MD, Andres Forrero-Torres, Sandra J Horning, MD, Brad S. Kahl, MD

Blood (2015) 126 (23): 2702.

https://doi.org/10.1182/blood.V126.23.2702.2702

Published: 2015

Journal Articles

The VcR-CVAD Regimen Produces a High Complete Response Rate in Untreated Mantle Cell Lymphoma (MCL): First Analysis of E1405 – A Phase II Study of VcR-CVAD with Maintenance Rituximab for MCL.

Brad S Kahl, MD, Hailun Li, Ph.D., Mitchell R Smith, MD, PhD, Randy D. Gascoyne, MD, Elisabeth Paietta, MD, Ranjana Advani, MD, Sandra J Horning, MD

Blood (2009) 114 (22): 1661.

https://doi.org/10.1182/blood.V114.22.1661.1661

Published: 2009

Journal Articles

Phase II Study of R-CHOP Followed by 90 Y-Ibritumomab Tiuxetan in Untreated Mantle Cell Lymphoma: Eastern Cooperative Oncology Group Study E1499.

Mitchell R. Smith, MD, PhD, Lijun Zhang, Leo I. Gordon, MD, James Foran, MD, Brad Kahl, MD, Randy D. Gascoyne, MD, Ranjana Advani, MD, Elisabeth Paietta, MD, Edie Weller, PhD, Sandra J. Horning, MD

Blood (2007) 110 (11): 389.

https://doi.org/10.1182/blood.V110.11.389.389

Published: 2007

Journal Articles

Epigenetic Signatures Accurately Distinguish Leukemia Subtypes and Provide a More Comprehensive Representation of Differentially Regulated Genes Than Gene Expression Profiling.

Maria E. Figueroa, MD, Kenny Ye, PhD, Elisabeth Paietta, MD, John M. Greally, MB PhD, Ari M. Melnick, MD

Blood (2006) 108 (11): 735.

https://doi.org/10.1182/blood.V108.11.735.735

Published: 2006

Journal Articles

An Integrated Epigenomic Analysis Approach To Determine the Molecular Basis of Acute Leukemias.

Maria E. Figueroa, MD, Kenny M. Ye, PhD, Elisabeth Paietta, MD, John M. Greally, MD, PhD, Ari M. Melnick, MD

Blood (2005) 106 (11): 3276.

https://doi.org/10.1182/blood.V106.11.3276.3276

Published: 2005

NARROW

Initial Therapy for Mantle Cell Lymphoma with Abbreviated R-CHOP Followed By Y 90 -Ibritumomab Tiuxetan: Ten Year Follow-up of the Phase 2 ECOG-ACRIN Study E1499

The VcR-CVAD Regimen Produces a High Complete Response Rate in Untreated Mantle Cell Lymphoma (MCL): First Analysis of E1405 – A Phase II Study of VcR-CVAD with Maintenance Rituximab for MCL.

Phase II Study of R-CHOP Followed by 90 Y-Ibritumomab Tiuxetan in Untreated Mantle Cell Lymphoma: Eastern Cooperative Oncology Group Study E1499.

Epigenetic Signatures Accurately Distinguish Leukemia Subtypes and Provide a More Comprehensive Representation of Differentially Regulated Genes Than Gene Expression Profiling.

An Integrated Epigenomic Analysis Approach To Determine the Molecular Basis of Acute Leukemias.

Email alerts

ASH Publications

American Society of Hematology

Initial Therapy for Mantle Cell Lymphoma with Abbreviated R-CHOP Followed By Y 90 -Ibritumomab Tiuxetan: Ten Year Follow-up of the Phase 2 ECOG-ACRIN Study E1499

The VcR-CVAD Regimen Produces a High Complete Response Rate in Untreated Mantle Cell Lymphoma (MCL): First Analysis of E1405 – A Phase II Study of VcR-CVAD with Maintenance Rituximab for MCL.

Phase II Study of R-CHOP Followed by 90 Y-Ibritumomab Tiuxetan in Untreated Mantle Cell Lymphoma: Eastern Cooperative Oncology Group Study E1499.

Epigenetic Signatures Accurately Distinguish Leukemia Subtypes and Provide a More Comprehensive Representation of Differentially Regulated Genes Than Gene Expression Profiling.

An Integrated Epigenomic Analysis Approach To Determine the Molecular Basis of Acute Leukemias.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only